Advanced Search

Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Archive > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 March;57(1) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 March;57(1):6-20

CURRENT ISSUE   ARCHIVE   EPUB AHEAD OF PRINT   MOST READ   eTOC


THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 March;57(1):6-20

MIBG IN NEUROBLASTOMA 

    REVIEWS

Functional-metabolic imaging of neuroblastoma

Sharp S. E. 1, Parisi M. T. 2, Gelfand M. J. 1, Yanik G. A. 3, Shulkin B. L. 4

1 Department of Radiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA;
2 Department of Radiology, Seattle Children’s Hospital, Seattle, WA, USA;
3 Department of Pediatrics, University of Michigan Medical Center, Ann Arbor, MI, USA;
4 Department of Radiological Sciences, St. Jude Children’s Research Hospital, Memphis, TN, USA

Neuroblastoma is the third most common malignant solid tumor of childhood. It originates from primitive neural crest cells of the sympathetic nervous system. Many imaging procedures help guide therapy and predict outcomes. Anatomic imaging methods, such as CT and MRI, are most useful for evaluation of the primary tumor mass and nearby involved lymph nodes. Functional imaging tracers, such as [123I]MIBG, [18F]FDG, and [99mTc]MDP, are used to assess the extent of disease and to search for distant metastases. [123I]MIBG is the principal functional imaging tracer for the detection and monitoring of neuroblastoma. [18F]FDG PET/CT is an alternative that is valuable in tumors with poor or no MIBG-uptake. [99mTc]MDP bone scans may be useful to assess cortical bone metastases. This article will review the use of [123I]MIBG and other functional imaging agents for the management of patients with neuroblastoma.

language: English


FULL TEXT  REPRINTS

top of page